Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information - Consolidated Statements of Profit and Loss (Details)

v3.22.1
Segment Information - Consolidated Statements of Profit and Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disclosure of operating segments [line items]      
Revenue $ 322,921 $ 79,272 [1] $ 16,034 [1]
Cost of care delivery (289,672) (67,254) [1] (19,810) [1]
Other operating income (expense) (400,754) (173,042) (156,548)
Change in fair value of warrant liabilities 27,811 0 [1] 0 [1]
Exchange gain / (loss) 868 (2,836) [1] 17,075 [1]
Gain on sale of subsidiary 3,917 0 [1] 0 [1]
Gain on remeasurement of equity interest 10,495 0 [1] 0 [1]
Share of loss of equity-accounted investees (2,602) (1,124) [1] 0 [1]
Segment EBITDA (327,016) (164,984) (143,249)
Depreciation and amortization (35,004) (14,487) (2,496)
Operating loss (402,509) (175,511) [1] (162,820) [1]
Operating segment, excluding materially reconciling items      
Disclosure of operating segments [line items]      
Revenue 322,873 79,194 16,043
Operating segments      
Disclosure of operating segments [line items]      
Revenue 322,870 79,060 16,073
Cost of care delivery (297,130) (76,186) (26,240)
Other operating income (expense) (392,528) (158,942) (148,508)
Change in fair value of warrant liabilities 27,811    
Exchange gain / (loss) (265) 17,217 16,815
Gain on sale of subsidiary 2,687    
Gain on remeasurement of equity interest 10,495    
Share of loss of equity-accounted investees (2,602) (1,124)  
Segment EBITDA (328,662) (139,975) (141,860)
Reconciliation adjustments      
Disclosure of operating segments [line items]      
Revenue 51 212 (39)
Cost of care delivery 7,458 8,932 6,430
Other operating income (expense) (8,226) (14,100) (8,040)
Change in fair value of warrant liabilities 0    
Exchange gain / (loss) 1,133 (20,053) 260
Gain on sale of subsidiary 1,230    
Gain on remeasurement of equity interest 0    
Share of loss of equity-accounted investees 0 0  
Segment EBITDA 1,646 (25,009) (1,389)
Unallocated amounts      
Disclosure of operating segments [line items]      
Revenue 48 78 (9)
Inter-segment revenue      
Disclosure of operating segments [line items]      
Revenue 3 134 (30)
UK | Operating segment, excluding materially reconciling items      
Disclosure of operating segments [line items]      
Revenue 88,967 44,000 14,633
UK | Operating segments      
Disclosure of operating segments [line items]      
Revenue 91,172 45,194 18,714
Cost of care delivery (41,542) (34,600) (25,707)
Other operating income (expense) (114,975) (127,762) (119,895)
Change in fair value of warrant liabilities 0    
Exchange gain / (loss) (1,844) 403 314
Gain on sale of subsidiary 0    
Gain on remeasurement of equity interest 0    
Share of loss of equity-accounted investees 0 0  
Segment EBITDA (67,189) (116,765) (126,574)
UK | Inter-segment revenue      
Disclosure of operating segments [line items]      
Revenue (2,205) (1,194) (4,081)
US | Operating segment, excluding materially reconciling items      
Disclosure of operating segments [line items]      
Revenue 232,296 32,226 0
US | Operating segments      
Disclosure of operating segments [line items]      
Revenue 228,332 29,132 (2,669)
Cost of care delivery (253,998) (34,381) (160)
Other operating income (expense) (105,602) (27,190) (23,273)
Change in fair value of warrant liabilities 0    
Exchange gain / (loss) 189 (246) (83)
Gain on sale of subsidiary 0    
Gain on remeasurement of equity interest 0    
Share of loss of equity-accounted investees (2,602) 0  
Segment EBITDA (133,681) (32,685) (26,185)
US | Inter-segment revenue      
Disclosure of operating segments [line items]      
Revenue 3,964 3,094 2,669
All other segments | Operating segment, excluding materially reconciling items      
Disclosure of operating segments [line items]      
Revenue 1,610 2,968 1,410
All other segments | Operating segments      
Disclosure of operating segments [line items]      
Revenue 3,366 4,734 28
Cost of care delivery (1,590) (7,205) (373)
Other operating income (expense) (171,951) (3,990) (5,340)
Change in fair value of warrant liabilities 27,811    
Exchange gain / (loss) 1,390 17,060 16,584
Gain on sale of subsidiary 2,687    
Gain on remeasurement of equity interest 10,495    
Share of loss of equity-accounted investees 0 (1,124)  
Segment EBITDA (127,792) 9,475 10,899
All other segments | Inter-segment revenue      
Disclosure of operating segments [line items]      
Revenue $ (1,756) $ (1,766) $ 1,382
[1] Restated to reflect reclassification of certain expense items described in Note 2.